In a rare move, the U.S. Food and Drug Administration has green-lighted two separate clinical trials to test the effectiveness of a marijuana derivative in treating pediatric epilepsy.
Our Colorado marijuana lawyers know that the drug has already been prescribed by many doctors for this very purpose – and to a reported significant degree of success. In many cases, doctors prescribe a form of the drug called cannabidiol (CBD), which does not contain the psychoactive ingredients typically present in the plant. This makes it a particularly attractive option for treating children.
However, the documented successes of the drug for treating epilepsy have not been made “official,” due to lack of any significant clinical trials. But clinical trials involving controlled substances – particularly those classified as Schedule I controlled substances – must be approved by the federal government, which makes them exceedingly rare.
Continue reading